MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
Key Highlights
- ➤Lorigerlimab confirmed ORR 25% in advanced clear cell gynecologic cancer
- ➤Disease control rate reached 44% among response-evaluable CCGC patients
- ➤Grade ≥3 treatment-related adverse events occurred in 49% of patients
- ➤MacroGenics enrolling 20 additional CCGC patients at 3 mg/kg Q3W
- ➤Updated LINNET results expected in first half of 2027
Expert Statements
Amir Jazaeri, Professor and Vice Chair for Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center; lead author
“Clear cell gynecologic malignancies are notoriously aggressive, resistant to conventional platinum-based chemotherapies, and carry a poor prognosis. New targeted treatments are urgently needed.”
Amir Jazaeri, Professor and Vice Chair for Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center; lead author
“The 25% response rate and manageable tolerability profile in CCGC observed in the LINNET study represent a highly encouraging potential therapeutic signal for a single agent in this difficult-to-treat histological subtype.”
Eric Risser, President and Chief Executive Officer of MacroGenics
“We are encouraged by the efficacy and manageable safety profile demonstrated in the Phase 2 LINNET study to date and these results mark an important milestone for lorigerlimab and highlight its potential for treating patients facing clear cell gynecologic cancers.”
Eric Risser, President and Chief Executive Officer of MacroGenics
“We believe these data support the promise of dual PD-1/CTLA-4 blockade and lorigerlimab’s potential to improve the treatment paradigm for this underserved patient population.”
* Single agent lorigerlimab demonstrated encouraging preliminary clinical activity in clear cell gynecologic cancer (CCGC) with a confirmed ORR of 25% and a DCR of 44% * Safety profile was manageable; further dose optimization being pursued with lower dose of 3 mg/kg Q3W * Anticipate sharing updated LINNET results in first half of 2027 ROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
“Clear cell gynecologic malignancies are notoriously aggressive, resistant to conventional platinum-based chemotherapies, and carry a poor prognosis. New targeted treatments are urgently needed,” said Amir Jazaeri, M.D., Professor and Vice Chair for Clinical Research in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, and lead author of the poster. “The 25% response rate and manageable tolerability profile in CCGC observed in the LINNET study represent a highly encouraging potential therapeutic signal for a single agent in this difficult-to-treat histological subtype.”
Get started
Create a free account to read the full story.